IBS-C Drugs market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global IBS-C Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.
For United States market, this report focuses on the IBS-C Drugs market size by players, by Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.
Segment by Type
- Linaclotide
- Lubiprostone
- Osmotic Laxatives
- Stimulant Laxatives
- Others
Segment by Application
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia
- Taiwan
- Indonesia
- Thailand
- Malaysia
- Philippines
- Vietnam
- Latin America
- Mexico
- Brazil
- Argentina
- Middle East & Africa
- Turkey
- Saudi Arabia
- U.A.E
By Company
- Catalent Pharmaceuticals Solutions
- Nestle
- Abbott Laboratories
- Synergy Pharmaceuticals
- Sucampo Pharmaceuticals
- Novartis Pharma Ag
- Astellas Pharmaceuticals
- Ardelyx, Inc
- Synthetic Biologics, Inc
- Teva Pharmaceutical Industries
- Bama-Geve, SLU
- Ferring BV
- Ironwood Pharmaceuticals, Inc
- Salix Pharmaceuticals Ltd
- Norgine B.V
- Prometheus Laboratories Inc
- Actavis Nordic A/S
- Albireo Pharma Inc
- Yuhan Corp
- Astrazeneca Plc
- The Menarini Group
- Ono Pharmaceutical Co., Ltd
